The Gujarat Kidney IPO closed for subscription on December 24, receiving a moderate overall response from investors. The IPO, which opened on December 22, was subscribed 5.09 times by the end of Day 3 with a healthy interest, particularly from retail investors, despite muted grey market signals.
Gujarat Kidney IPO Subscription Status
As per the latest data available at 3:54 PM on December 24, 2025, the Gujarat Kidney IPO subscription status showed strong participation from individual investors. The retail category was subscribed 18.34 times, while non-institutional investors (NII) subscribed to the issue 5.68 times. The QIB (excluding anchor investors) portion saw relatively modest demand at 1.06 times.
Gujarat Kidney IPO GMP Today Remains Flat
Despite decent subscription numbers, the Gujarat Kidney IPO GMP today remains muted. The latest grey market premium stands at Rs 0 as of December 24. The estimated listing price is also Rs. 114, the same as the issue price band, pointing to expectations of a flat listing with no immediate listing gains.
Gujarat Kidney IPO Details
The Gujarat Kidney IPO is a public issue worth Rs. 250.80 crore and consists entirely of a fresh issue of 2.20 crore equity shares, with no offer-for-sale component. The price band for the IPO was set at Rs. 108 to Rs. 114 per share, while the lot size was fixed at 128 shares. For retail investors, the minimum investment amount stood at Rs. 14,592, calculated at the upper price band.
Gujarat Kidney IPO Allotment and Listing Date
Investors who applied for the issue are now awaiting the next key timelines. The Gujarat Kidney IPO allotment is expected to be finalised on December 26, 2025. The shares are scheduled to be listed on both the BSE and NSE, with a tentative listing date of December 30, 2025. Applicants will be able to check their allotment status through the registrar’s website once announced.
BP Wealth’s View on Gujarat Kidney IPO
Brokerage firm BP Wealth has maintained a “SUBSCRIBE” rating on the Gujarat Kidney IPO. In its report, the broking highlighted the company’s asset-light hospital expansion strategy, which focuses on selective acquisitions and operational control to achieve faster growth with lower capital intensity.
According to BP Wealth, at the upper price band of Rs. 114, the company is valued at a P/E multiple of 61.6x FY25 earnings. Despite being smaller in scale compared to listed peers, the broking believes the company compares favourably due to strong demand for speciality healthcare services and supportive government policies in Gujarat.